Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:739-745
doi: 10.1161/hc0602.103393
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weis, M.
Right arrow Articles by Cooke, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weis, M.
Right arrow Articles by Cooke, J. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
Medline Plus Health Information
*Statins
Related Collections
Right arrow Angiogenesis
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2002;105:739.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Statins Have Biphasic Effects on Angiogenesis

Michael Weis, MD; Christopher Heeschen, MD; Alec J. Glassford, BS; John P. Cooke, MD, PhD

From Stanford University School of Medicine, Division of Cardiovascular Medicine, Stanford, Calif.

Correspondence to John P. Cooke, Stanford University School of Medicine, Division of Cardiovascular Medicine, 300 Pasteur Dr, Stanford, CA 94305. E-mail john.cooke{at}stanford.edu

Background Statins inhibit HMG-CoA reductase to reduce the synthesis of cholesterol and isoprenoids that modulate diverse cell functions. We investigated the effect of the statins cerivastatin and atorvastatin on angiogenesis in vitro and in vivo.

Methods and Results Endothelial cell proliferation, migration, and differentiation were enhanced at low concentrations (0.005 to 0.01 µmol/L) but significantly inhibited at high statin concentrations (0.05 to 1 µmol/L). Antiangiogenic effects at high concentrations were associated with decreased endothelial release of vascular endothelial growth factor and increased endothelial apoptosis and were reversed by geranylgeranyl pyrophosphate. In murine models, inflammation-induced angiogenesis was enhanced with low-dose statin therapy (0.5 mg · kg-1 · d-1) but significantly inhibited with high concentrations of cerivastatin or atorvastatin (2.5 mg · kg-1 · d-1). Despite the fact that high-dose statin treatment was effective at reducing lipid levels in hyperlipidemic apolipoprotein E–deficient mice, it impaired rather than enhanced angiogenesis. Finally, high-dose cerivastatin decreased tumor growth and tumor vascularization in a murine Lewis lung cancer model.

Conclusions HMG-CoA reductase inhibition has a biphasic dose-dependent effect on angiogenesis that is lipid independent and associated with alterations in endothelial apoptosis and vascular endothelial growth factor signaling. Statins have proangiogenic effects at low therapeutic concentrations but angiostatic effects at high concentrations that are reversed by geranylgeranyl pyrophosphate. At clinically relevant doses, statins may modulate angiogenesis in humans via effects on geranylated proteins.


Key Words: endothelium • inflammation • apoptosis • hypoxia • lipids




This article has been cited by other articles:


Home page
IOVSHome page
M. Bartoli, M. Al-Shabrawey, M. Labazi, M. A. Behzadian, M. Istanboli, A. B. El-Remessy, R. W. Caldwell, D. M. Marcus, and R. B. Caldwell
HMG-CoA Reductase Inhibitors (Statin) Prevents Retinal Neovascularization in a Model of Oxygen-Induced Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4934 - 4940.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al.
Future perspectives for the treatment of pulmonary arterial hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S108 - S117.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Saito, V. Dubreuil, Y. Arai, M. Wilsch-Brauninger, D. Schwudke, G. Saher, T. Miyata, G. Breier, C. Thiele, A. Shevchenko, et al.
Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis
PNAS, May 19, 2009; 106(20): 8350 - 8355.
[Abstract] [Full Text] [PDF]


Home page
Heart AsiaHome page
A M Tonkin, A Forbes, and S J Haas
The evidence on trial: cholesterol lowering and cancer
Heart Asia, March 6, 2009; 2009(2): 6 - 10.
[Full Text] [PDF]


Home page
Circ. Res.Home page
G. Suzuki, V. Iyer, T. Cimato, and J. M. Canty Jr
Pravastatin Improves Function in Hibernating Myocardium by Mobilizing CD133+ and cKit+ Bone Marrow Progenitor Cells and Promoting Myocytes to Reenter the Growth Phase of the Cardiac Cell Cycle
Circ. Res., January 30, 2009; 104(2): 255 - 264.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. J. Hamilton, K. C. Goldberg, E. A. Platz, and S. J. Freedland
The Influence of Statin Medications on Prostate-specific Antigen Levels
J Natl Cancer Inst, November 5, 2008; 100(21): 1511 - 1518.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. Herrler, M. Bohm, and C. Heeschen
More good reasons for adherence to statin therapy during acute coronary syndromes
Eur. Heart J., September 1, 2008; 29(17): 2061 - 2063.
[Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
C. J.-Y. Hou, C.-H. Tsai, C.-H. Su, Y.-J. Wu, S.-J. Chen, J.-J. Chiu, M.-S. Shiao, and H.-I Yeh
Diabetes Reduces Aortic Endothelial Gap Junctions in ApoE-deficient Mice: Simvastatin Exacerbates the Reduction
J. Histochem. Cytochem., August 1, 2008; 56(8): 745 - 752.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Settergren, F. Bohm, L. Ryden, and J. Pernow
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Eur. Heart J., July 2, 2008; 29(14): 1753 - 1760.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Takahashi, H. Nakamura, M. Seki, Y. Shiraishi, M. Yamamoto, M. Furuuchi, T. Nakajima, S. Tsujimura, T. Shirahata, M. Nakamura, et al.
Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice
Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L882 - L890.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Dulak, J. Deshane, A. Jozkowicz, and A. Agarwal
Heme Oxygenase-1 and Carbon Monoxide in Vascular Pathobiology: Focus on Angiogenesis
Circulation, January 15, 2008; 117(2): 231 - 241.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
E. Fosslien
Cancer Morphogenesis: Role of Mitochondrial Failure
Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 307 - 330.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Boodhwani, S. Mieno, J. Feng, N. R. Sodha, R. T. Clements, S.-H. Xu, and F. W. Sellke
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine
J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 117 - 122.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al.
Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Zhang, Z. G. Zhang, X. S. Liu, A. Hozeska-Solgot, and M. Chopp
The PI3K/Akt Pathway Mediates the Neuroprotective Effect of Atorvastatin in Extending Thrombolytic Therapy After Embolic Stroke in the Rat
Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2470 - 2475.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al.
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Blood, October 1, 2007; 110(7): 2674 - 2684.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Boodhwani and F. W. Sellke
Reply to the Editor.
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1686 - 1687.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Herrmann and A. Lerman
Atherosclerosis in the Back Yard
J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2102 - 2104.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu
High-dose atorvastatin causes regression of endometriotic implants: a rat model
Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. J. M. Greer, A. K. Kakkar, J. W. Elrod, L. J. Watson, S. P. Jones, and D. J. Lefer
Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2743 - H2751.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman
Angiogenesis in Atherogenesis
Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1948 - 1957.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
S Ranjit and L Dazhu
Potential role of dendritic cells for progression of atherosclerotic lesions.
Postgrad. Med. J., September 1, 2006; 82(971): 573 - 575.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. R. Chade, X. Zhu, O. P. Mushin, C. Napoli, A. Lerman, and L. O. Lerman
Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia
FASEB J, August 1, 2006; 20(10): 1706 - 1708.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Ushio-Fukai
Redox signaling in angiogenesis: Role of NADPH oxidase
Cardiovasc Res, July 15, 2006; 71(2): 226 - 235.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Boodhwani, Y. Nakai, P. Voisine, J. Feng, J. Li, S. Mieno, B. Ramlawi, C. Bianchi, R. Laham, and F. W. Sellke
High-Dose Atorvastatin Improves Hypercholesterolemic Coronary Endothelial Dysfunction Without Improving the Angiogenic Response
Circulation, July 4, 2006; 114(1_suppl): I-402 - I-408.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. J. Zambarakji, T. Nakazawa, E. Connolly, A. M. Lane, S. Mallemadugula, M. Kaplan, N. Michaud, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller
Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2623 - 2631.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T.-S. Li, M. Takahashi, R. Suzuki, T. Kobayashi, H. Ito, A. Mikamo, and K. Hamano
Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis
Ann. Thorac. Surg., June 1, 2006; 81(6): 2217 - 2225.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B.-K. Son, K. Kozaki, K. Iijima, M. Eto, T. Kojima, H. Ota, Y. Senda, K. Maemura, T. Nakano, M. Akishita, et al.
Statins Protect Human Aortic Smooth Muscle Cells From Inorganic Phosphate-Induced Calcification by Restoring Gas6-Axl Survival Pathway
Circ. Res., April 28, 2006; 98(8): 1024 - 1031.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer
Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
R. Sharma and D.-Z. Li
Role of Dendritic Cells in Atherosclerosis
Asian Cardiovasc Thorac Ann, April 1, 2006; 14(2): 166 - 169.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard
The Role of Statins in Cancer Therapy.
Oncologist, January 1, 2006; 11(3): 306 - 315.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Ii, H. Nishimura, K. F. Kusano, G. Qin, Y.-s. Yoon, A. Wecker, T. Asahara, and D. W. Losordo
Neuronal Nitric Oxide Synthase Mediates Statin-Induced Restoration of Vasa Nervorum and Reversal of Diabetic Neuropathy
Circulation, July 5, 2005; 112(1): 93 - 102.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Jacobi, K. Sydow, G. von Degenfeld, Y. Zhang, H. Dayoub, B. Wang, A. J. Patterson, M. Kimoto, H. M. Blau, and J. P. Cooke
Overexpression of Dimethylarginine Dimethylaminohydrolase Reduces Tissue Asymmetric Dimethylarginine Levels and Enhances Angiogenesis
Circulation, March 22, 2005; 111(11): 1431 - 1438.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Horiguchi, M. Sumitomo, J. Asakuma, T. Asano, T. Asano, and M. Hayakawa
3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis
Clin. Cancer Res., December 15, 2004; 10(24): 8648 - 8655.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. NAVARRO, B. ANAND-APTE, and M.-O. PARAT
A role for caveolae in cell migration
FASEB J, December 1, 2004; 18(15): 1801 - 1811.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S.-i. Yamagishi, R. Abe, Y. Inagaki, K. Nakamura, H. Sugawara, D. Inokuma, H. Nakamura, T. Shimizu, M. Takeuchi, A. Yoshimura, et al.
Minodronate, a Newly Developed Nitrogen-Containing Bisphosphonate, Suppresses Melanoma Growth and Improves Survival in Nude Mice by Blocking Vascular Endothelial Growth Factor Signaling
Am. J. Pathol., December 1, 2004; 165(6): 1865 - 1874.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Ito, T. Adachi, D. R. Pimentel, Y. Ido, and W. S. Colucci
Statins Inhibit {beta}-Adrenergic Receptor-Stimulated Apoptosis in Adult Rat Ventricular Myocytes via a Rac1-Dependent Mechanism
Circulation, July 27, 2004; 110(4): 412 - 418.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. Zeng, H. Xu, T.-L. Chew, R. Chisholm, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh
Simvastatin Modulates Angiotensin II Signaling Pathway by Preventing Rac1-Mediated Upregulation of p27
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1711 - 1720.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett
Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis
Circulation, June 15, 2004; 109(23): 2826 - 2831.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, P. Stewen, and F. Fyhrquist
Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2096 - H2102.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. K. Liao
Statin Therapy: Having the Good Without the Bad
Hypertension, June 1, 2004; 43(6): 1171 - 1172.
[Full Text] [PDF]


Home page
HypertensionHome page
M. Sata, H. Nishimatsu, J.-i. Osuga, K. Tanaka, N. Ishizaka, S. Ishibashi, Y. Hirata, and R. Nagai
Statins Augment Collateral Growth in Response to Ischemia but They Do Not Promote Cancer and Atherosclerosis
Hypertension, June 1, 2004; 43(6): 1214 - 1220.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
X.-Y. Zhu, M. Rodriguez-Porcel, M. D. Bentley, A. R. Chade, V. Sica, C. Napoli, N. Caplice, E. L. Ritman, A. Lerman, and L. O. Lerman
Antioxidant Intervention Attenuates Myocardial Neovascularization in Hypercholesterolemia
Circulation, May 4, 2004; 109(17): 2109 - 2115.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
F. R. DANESH and Y. S. KANWAR
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy
FASEB J, May 1, 2004; 18(7): 805 - 815.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Miyahara, J. Kiryu, K. Yamashiro, K. Miyamoto, F. Hirose, H. Tamura, H. Katsuta, K. Nishijima, A. Tsujikawa, and Y. Honda
Simvastatin Inhibits Leukocyte Accumulation and Vascular Permeability in the Retinas of Rats with Streptozotocin-Induced Diabetes
Am. J. Pathol., May 1, 2004; 164(5): 1697 - 1706.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Zbinden, N Brunner, K Wustmann, M Billinger, B Meier, and C Seiler
Effect of statin treatment on coronary collateral flow in patients with coronary artery disease
Heart, April 1, 2004; 90(4): 448 - 449.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Y. Chong, G. J. Caine, B. Freestone, A. D. Blann, and G. Y. H. Lip
Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure
J. Am. Coll. Cardiol., February 4, 2004; 43(3): 423 - 428.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. M. Bell and D. M. Yellon
Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway
J. Am. Coll. Cardiol., February 5, 2003; 41(3): 508 - 515.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman
Statin effects beyond lipid lowering--are they clinically relevant?
Eur. Heart J., February 1, 2003; 24(3): 225 - 248.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W.M. van Hinsbergh
Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro
Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 211 - 217.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Skaletz-Rorowski, M. Lutchman, Y. Kureishi, D. J. Lefer, J. R. Faust, and K. Walsh
HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells
Cardiovasc Res, January 1, 2003; 57(1): 253 - 264.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Weis, C. L. Schlichting, E. G. Engleman, and J. P. Cooke
Endothelial Determinants of Dendritic Cell Adhesion and Migration: New Implications for Vascular Diseases
Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1817 - 1823.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Sata, J. P. Cooke, M. Weis, A. J. Glassford, and C. Heeschen
Biphasic Effects of Statins on Angiogenesis * Response
Circulation, September 10, 2002; 106 (11): e47 - e47.
[Full Text] [PDF]


Home page
Circ. Res.Home page
H.-J. Park, D. Kong, L. Iruela-Arispe, U. Begley, D. Tang, and J. B. Galper
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA
Circ. Res., July 26, 2002; 91(2): 143 - 150.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Shiojima and K. Walsh
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Circ. Res., June 28, 2002; 90(12): 1243 - 1250.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. C. Yeung and P. Tsao
Statin Therapy: Beyond Cholesterol Lowering and Antiinflammatory Effects
Circulation, June 25, 2002; 105(25): 2937 - 2938.
[Full Text] [PDF]